GW PHARMA
GW Pharma focuses on the development and commercialization of innovative drugs for indications in the mental area (CNS), and hopes to provide faster, more effective and safer treatments for unmet needs in the clinical antidepressant field. drug. The team members have rich experience in CNS new drug research and development, and product pipelines are arranged around depression and anxiety. The current data of the company's core products proves that it has obvious safety advantages compared with the products already on the market.
GW PHARMA
Industry:
Health Care
Founded:
2016-01-01
Address:
Beijing, Beijing, China
Country:
China
Status:
Active
Total Funding:
0
Similar Organizations
PolyCore Therapeutics
PolyCore Therapeutics’ team of life sciences scientists is dedicated to developing breakthrough treatments for CNS Diseases.
Investors List
Dynamic Balance Capital
Dynamic Balance Capital investment in Seed Round - GW Pharma
Tengye Ventures
Tengye Ventures investment in Seed Round - GW Pharma
More informations about "GW Pharma"
Jazz Pharmaceuticals Completes Acquisition of GW …
May 5, 2021 The Company plans to provide 2021 financial guidance for the combined Jazz/GW organization within the next 45 days. Under the terms of the agreement, holders of GW ADSs, …See details»
Transforming Together: What Our Recent ... - Jazz Pharmaceuticals
With more than two decades spent pioneering cannabinoid science, GW Pharmaceuticals CEO Justin Gover and his team have built an impressive commercial portfolio and innovative …See details»
Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating …
DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered …See details»
Jazz to Acquire GW Pharmaceuticals
GW Pharmaceuticals Shareholders Approve Acquisition …
Apr 23, 2021 About Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the ...See details»
GW Pharmaceuticals : Jazz Pharmaceuticals Completes Acquisition …
DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW"), a leader …See details»
GW Pharmaceuticals plc - AnnualReports.com
GW Pharmaceuticals is a cutting-edge UK-based biopharmaceutical company that over the last 20 years has established a world-leading position in cannabinoid science and the development of regulatory approved medicines derived from …See details»
Jazz Pharmaceuticals Completes Acquisition of GW ... - BioSpace
DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW"), a leader …See details»
Jazz Pharma to buy GW Pharma for $7.2 bln, adding …
Feb 3, 2021 Jazz Pharmaceuticals Plc (JAZZ.O) said on Wednesday it had agreed to buy GW Pharmaceuticals plc (GWPH.O) in a $7.2 billion cash-and-stock deal which will bolster its neuroscience business with the ...See details»
Transforming Together: What Our Recent Acquisition …
May 5, 2021 With more than two decades spent pioneering cannabinoid science, GW Pharmaceuticals CEO Justin Gover and his team have built an impressive commercial portfolio and innovative pipeline of early and ...See details»
GW Pharmaceuticals Shareholders Approve Acquisition by Jazz
Apr 23, 2021 GW Pharmaceuticals Investor Contact: Scott Giacobello, Chief Financial Officer [email protected] +1 (760) 795 2200. Jazz Pharmaceuticals Media Contact: …See details»
Jazz agrees $7.2bn deal for British cannabis pioneer GW …
Feb 3, 2021 Jazz Pharmaceuticals has agreed to buy GW Pharmaceuticals, a British pioneer in cannabis-based medicines, in a $7.2bn cash-and-stock deal that will expand the US …See details»
CREATING AN INNOVATIVE, HIGH-GROWTH, GLOBAL …
Feb 3, 2021 2020, GW Pharmaceuticals’ Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the quarter ended September 30, …See details»
Jazz Pharmaceuticals Completes Acquisition of GW …
May 6, 2021 The Company plans to provide 2021 financial guidance for the combined Jazz/GW organization within the next 45 days. Under the terms of the agreement, holders of GW ADSs, …See details»
GW Pharmaceuticals - Crunchbase Company Profile & Funding
GW Pharmaceuticals closed its last funding round on Oct 2, 2018 from a Post-IPO Equity round. Who are GW Pharmaceuticals 's competitors? Alternatives and possible competitors to GW …See details»
Jazz Pharmaceuticals Completes Acquisition of GW …
May 6, 2021 The Company plans to provide 2021 financial guidance for the combined Jazz/GW organization within the next 45 days. Under the terms of the agreement, holders of GW ADSs, …See details»
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End
On Feb. 3, 2021, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW announced the companies had entered into a definitive agreement for Jazz to acquire GW for $220.00 per American …See details»
GW Pharma to Settle Jazz Pharma Buyout Suit for $7.5 Million
Mar 26, 2024 GW Pharmaceuticals and its leaders will pay $7.5 million to end shareholder allegations that they filed a deficient proxy statement to win votes for Jazz Pharmaceuticals …See details»
Jazz Pharmaceuticals Completes Acquisition of GW ... - Nasdaq
May 5, 2021 --Jazz Pharmaceuticals today announced the completion of its acquisition of GW Pharmaceuticals plc, a leader in the science, development and commercialization of …See details»